Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 58

1.

Combined transcriptomic-(1)H NMR metabonomic study reveals that monoethylhexyl phthalate stimulates adipogenesis and glyceroneogenesis in human adipocytes.

Ellero-Simatos S, Claus SP, Benelli C, Forest C, Letourneur F, Cagnard N, Beaune PH, de Waziers I.

J Proteome Res. 2011 Dec 2;10(12):5493-502. doi: 10.1021/pr200765v. Epub 2011 Nov 9.

2.

Effect of cytochrome P450 2C19 genotype on voriconazole exposure in cystic fibrosis lung transplant patients.

Berge M, Guillemain R, Trégouet DA, Amrein C, Boussaud V, Chevalier P, Lillo-Lelouet A, Le Beller C, Laurent-Puig P, Beaune PH, Billaud EM, Loriot MA.

Eur J Clin Pharmacol. 2011 Mar;67(3):253-60. doi: 10.1007/s00228-010-0914-2. Epub 2010 Oct 31.

PMID:
21038076
3.

[Molecular pharmacogenetics in hospital laboratories in France: current data and future prospects].

Allorge D, Beaune PH, Becquemont L, Bessard G, Bezieau S, Boisdron-Celle M, Boyer JC, Broly F, Dhaneens CM, Fonrose X, Gagnieu MC, Gamelin E, Gozé C, Jacqz-Aigrain E, Loric S, Loriot MA, Marquet P, Morel A, Namour B, Paintaud G, Peoc'h K, Picard N, Watier H, Verstuyft C.

Ann Pharm Fr. 2007 Nov;65(6):371-81. Review. French.

PMID:
18079669
4.

[Pharmacogenetics: from basic research to clinical applications].

Beaune PH.

Ann Pharm Fr. 2007 Nov;65(6):365-70. Review. French.

PMID:
18079668
5.

Scaling factors for the extrapolation of in vivo metabolic drug clearance from in vitro data: reaching a consensus on values of human microsomal protein and hepatocellularity per gram of liver.

Barter ZE, Bayliss MK, Beaune PH, Boobis AR, Carlile DJ, Edwards RJ, Houston JB, Lake BG, Lipscomb JC, Pelkonen OR, Tucker GT, Rostami-Hodjegan A.

Curr Drug Metab. 2007 Jan;8(1):33-45. Review.

PMID:
17266522
6.

Determination of cytochrome P450 2D6 (CYP2D6) gene copy number by real-time quantitative PCR.

Bodin L, Beaune PH, Loriot MA.

J Biomed Biotechnol. 2005;2005(3):248-53.

7.

Pharmacogenetics of acenocoumarol pharmacodynamics.

Morin S, Bodin L, Loriot MA, Thijssen HH, Robert A, Strabach S, Verstuyft C, Tregouet DA, Dubert L, Laurent-Puig P, Funck-Brentano C, Jaillon P, Beaune PH, Becquemont L.

Clin Pharmacol Ther. 2004 May;75(5):403-14.

PMID:
15116053
8.

Indirect cytotoxicity of flucloxacillin toward human biliary epithelium via metabolite formation in hepatocytes.

Lakehal F, Dansette PM, Becquemont L, Lasnier E, Delelo R, Balladur P, Poupon R, Beaune PH, Housset C.

Chem Res Toxicol. 2001 Jun;14(6):694-701.

PMID:
11409940
9.

Is diclofenac a valuable CYP2C9 probe in humans?

Morin S, Loriot MA, Poirier JM, Tenneze L, Beaune PH, Funck-Brentano C, Jaillon P, Becquemont L.

Eur J Clin Pharmacol. 2001 Jan-Feb;56(11):793-7.

PMID:
11294368
10.

Cytochrome P4502C9 is the principal catalyst of racemic acenocoumarol hydroxylation reactions in human liver microsomes.

Thijssen HH, Flinois JP, Beaune PH.

Drug Metab Dispos. 2000 Nov;28(11):1284-90.

PMID:
11038154
11.

Phase I and phase II drug-metabolizing enzymes are expressed and heterogeneously distributed in the biliary epithelium.

Lakehal F, Wendum D, Barbu V, Becquemont L, Poupon R, Balladur P, Hannoun L, Ballet F, Beaune PH, Housset C.

Hepatology. 1999 Dec;30(6):1498-506.

PMID:
10573530
12.

Drug-induced immunotoxicity.

Dansette PM, Bonierbale E, Minoletti C, Beaune PH, Pessayre D, Mansuy D.

Eur J Drug Metab Pharmacokinet. 1998 Oct-Dec;23(4):443-51. Review.

PMID:
10323325
13.

High yield purification and characterization of engineered human P450 1A2 and generation of immuno-inhibitor antibodies.

Louërat-Oriou B, Flinois JP, Beaune PH, Pompon D.

Pharmacogenetics. 1999 Feb;9(1):61-70.

PMID:
10208644
14.

Autoantibodies against a kidney--liver protein associated with quinolone-induced acute interstitial nephritis or hepatitis.

Gauffre A, Mircheva J, Glotz D, Fillastre JP, Simon P, Beaune PH, Druet P.

Nephrol Dial Transplant. 1997 Sep;12(9):1961-2.

PMID:
9306350
15.

Epitope mapping of human CYP1A2 in dihydralazine-induced autoimmune hepatitis.

Belloc C, Gauffre A, André C, Beaune PH.

Pharmacogenetics. 1997 Jun;7(3):181-6.

PMID:
9241657
16.

The use of human in vitro metabolic parameters to explore the risk assessment of hazardous compounds: the case of ethylene dibromide.

Ploemen JP, Wormhoudt LW, Haenen GR, Oudshoorn MJ, Commandeur JN, Vermeulen NP, de Waziers I, Beaune PH, Watabe T, van Bladeren PJ.

Toxicol Appl Pharmacol. 1997 Mar;143(1):56-69.

PMID:
9073592
17.

Immunotoxicology of the liver: adverse reactions to drugs.

Beaune PH, Lecoeur S.

J Hepatol. 1997;26 Suppl 2:37-42. Review.

PMID:
9204408
18.

CYP3A5 is the major cytochrome P450 3A expressed in human colon and colonic cell lines.

Gervot L, Carrière V, Costet P, Cugnenc PH, Berger A, Beaune PH, de Waziers I.

Environ Toxicol Pharmacol. 1996 Dec 20;2(4):381-8.

PMID:
21781746
19.

Inter-individual variability in the oxidation of 1,2-dibromoethane: use of heterologously expressed human cytochrome P450 and human liver microsomes.

Wormhoudt LW, Ploemen JH, de Waziers I, Commandeur JN, Beaune PH, van Bladeren PJ, Vermeulen NP.

Chem Biol Interact. 1996 Sep 6;101(3):175-92.

PMID:
8870687
21.

Human cytochromes P450 expressed in Escherichia coli: production of specific antibodies.

Belloc C, Baird S, Cosme J, Lecoeur S, Gautier JC, Challine D, de Waziers I, Flinois JP, Beaune PH.

Toxicology. 1996 Jan 8;106(1-3):207-19.

PMID:
8571393
22.

Anti-cytochrome P450 autoantibodies in drug-induced disease.

Beaune PH, Lecoeur S, Bourdi M, Gauffre A, Belloc C, Dansette P, Mansuy D.

Eur J Haematol Suppl. 1996;60:89-92. Review.

PMID:
8987248
23.

Use of heterologous expression systems to study autoimmune drug-induced hepatitis.

Lecoeur S, Gautier JC, Belloc C, Gauffre A, Beaune PH.

Methods Enzymol. 1996;272:76-85. No abstract available.

PMID:
8791764
24.

Identification of the highly polymorphic S-mephenytoin hydroxylase in humans.

Soucek P, Guo Z, Sandhu P, Martin MV, Cosme J, Beaune PH, Guengerich FP.

Arch Toxicol Suppl. 1996;18:437. No abstract available.

PMID:
8678819
25.

Insulin down-regulates cytochrome P450 2B and 2E expression at the post-transcriptional level in the rat hepatoma cell line.

De Waziers I, Garlatti M, Bouguet J, Beaune PH, Barouki R.

Mol Pharmacol. 1995 Mar;47(3):474-9.

PMID:
7700245
26.

Expression of cytochrome P450 in rat pleural mesothelial cells in secondary cultures.

Buard A, Beaune PH, Renier A, Jaurand MC, Bignon J, Laurent P.

J Cell Physiol. 1994 Jul;160(1):176-83.

PMID:
8021296
27.
28.

Specificity of in vitro covalent binding of tienilic acid metabolites to human liver microsomes in relationship to the type of hepatotoxicity: comparison with two directly hepatotoxic drugs.

Lecoeur S, Bonierbale E, Challine D, Gautier JC, Valadon P, Dansette PM, Catinot R, Ballet F, Mansuy D, Beaune PH.

Chem Res Toxicol. 1994 May-Jun;7(3):434-42.

PMID:
8075377
29.

Identification of the major human hepatic cytochrome P450 involved in activation and N-dechloroethylation of ifosfamide.

Walker D, Flinois JP, Monkman SC, Beloc C, Boddy AV, Cholerton S, Daly AK, Lind MJ, Pearson AD, Beaune PH, et al.

Biochem Pharmacol. 1994 Mar 29;47(7):1157-63.

PMID:
8161344
30.

Principal xenobiotic-metabolizing enzyme systems in human head and neck squamous cell carcinoma.

Janot F, Massaad L, Ribrag V, de Waziers I, Beaune PH, Luboinski B, Parise O Jr, Gouyette A, Chabot GG.

Carcinogenesis. 1993 Jul;14(7):1279-83.

PMID:
8330340
31.

Autoantibodies against cytochromes P-450 in drug-induced autoimmune hepatitis.

Beaune PH, Bourdi M.

Ann N Y Acad Sci. 1993 Jun 23;685:641-5. No abstract available.

PMID:
8363271
32.

[Screening of principal enzymes involved in the metabolism of anticancer drugs in human and murine colonic tumors].

Massaad L, de Waziers I, Ribrag V, Janot F, Morizet J, Beaune PH, Gouyette A, Chabot GG.

Bull Cancer. 1993 May;80(5):397-407. French.

PMID:
8173193
33.

Human-liver cytochromes P-450 expressed in yeast as tools for reactive-metabolite formation studies. Oxidative activation of tienilic acid by cytochromes P-450 2C9 and 2C10.

Lopez Garcia MP, Dansette PM, Valadon P, Amar C, Beaune PH, Guengerich FP, Mansuy D.

Eur J Biochem. 1993 Apr 1;213(1):223-32.

34.

Comparison of mouse and human colon tumors with regard to phase I and phase II drug-metabolizing enzyme systems.

Massaad L, de Waziers I, Ribrag V, Janot F, Beaune PH, Morizet J, Gouyette A, Chabot GG.

Cancer Res. 1992 Dec 1;52(23):6567-75.

35.

Nature of cytochromes P450 involved in the 2-/4-hydroxylations of estradiol in human liver microsomes.

Kerlan V, Dreano Y, Bercovici JP, Beaune PH, Floch HH, Berthou F.

Biochem Pharmacol. 1992 Nov 3;44(9):1745-56.

PMID:
1449532
36.

Anti-liver microsomes autoantibodies and dihydralazine-induced hepatitis: specificity of autoantibodies and inductive capacity of the drug.

Bourdi M, Gautier JC, Mircheva J, Larrey D, Guillouzo A, Andre C, Belloc C, Beaune PH.

Mol Pharmacol. 1992 Aug;42(2):280-5.

PMID:
1513326
37.

Cytochrome P450 induction and mutagenicity of 2-aminoanthracene (2AA) in rat liver and gut.

Carrière V, de Waziers I, Courtois YA, Leroux JP, Beaune PH.

Mutat Res. 1992 Jul;268(1):11-20.

PMID:
1378177
38.

Interspecies variations in caffeine metabolism related to cytochrome P4501A enzymes.

Berthou F, Guillois B, Riche C, Dreano Y, Jacqz-Aigrain E, Beaune PH.

Xenobiotica. 1992 Jun;22(6):671-80.

PMID:
1441590
39.

Characterization of human lung microsomal cytochrome P-450 1A1 and its role in the oxidation of chemical carcinogens.

Shimada T, Yun CH, Yamazaki H, Gautier JC, Beaune PH, Guengerich FP.

Mol Pharmacol. 1992 May;41(5):856-64.

PMID:
1588920
40.

Metabolism rate of oxodipine in rats and humans: comparison of in vivo and in vitro data.

Flinois JP, Chabin M, Egros F, Dufour A, de Waziers I, Mas-Chamberlin C, Beaune PH.

J Pharmacol Exp Ther. 1992 Apr;261(1):381-6.

PMID:
1560383
41.

Effects of ethanol, dexamethasone and RU 486 on expression of cytochromes P450 2B, 2E, 3A and glutathione transferase pi in a rat hepatoma cell line (Fao).

de Waziers I, Bouguet J, Beaune PH, Gonzalez FJ, Ketterer B, Barouki R.

Pharmacogenetics. 1992 Feb;2(1):12-8.

PMID:
1302037
42.

Effects of ethanol and clofibrate on expression of cytochrome P-450 enzymes and epoxide hydrolase in cultures and cocultures of rat hepatocytes.

Perrot N, Chesné C, De Waziers I, Conner J, Beaune PH, Guillouzo A.

Eur J Biochem. 1991 Aug 15;200(1):255-61.

43.

Separation of human liver microsomal tolbutamide hydroxylase and (S)-mephenytoin 4'-hydroxylase cytochrome P-450 enzymes.

Srivastava PK, Yun CH, Beaune PH, Ged C, Guengerich FP.

Mol Pharmacol. 1991 Jul;40(1):69-79.

PMID:
1857342
44.

Drug-metabolizing enzyme expression in human normal, peritumoral and tumoral colorectal tissue samples.

de Waziers I, Cugnenc PH, Berger A, Leroux JP, Beaune PH.

Carcinogenesis. 1991 May;12(5):905-9.

PMID:
2029756
46.

Hydroxylation of chlorzoxazone as a specific probe for human liver cytochrome P-450IIE1.

Peter R, Böcker R, Beaune PH, Iwasaki M, Guengerich FP, Yang CS.

Chem Res Toxicol. 1990 Nov-Dec;3(6):566-73. Erratum in: Chem Res Toxicol 1991 May-Jun;4(3):389.

PMID:
2103328
47.

Expression of cytochrome P-450 enzymes in cultured human hepatocytes.

Morel F, Beaune PH, Ratanasavanh D, Flinois JP, Yang CS, Guengerich FP, Guillouzo A.

Eur J Biochem. 1990 Jul 31;191(2):437-44.

48.

Anti-liver endoplasmic reticulum autoantibodies are directed against human cytochrome P-450IA2. A specific marker of dihydralazine-induced hepatitis.

Bourdi M, Larrey D, Nataf J, Bernuau J, Pessayre D, Iwasaki M, Guengerich FP, Beaune PH.

J Clin Invest. 1990 Jun;85(6):1967-73.

49.

Cytochrome P 450 isoenzymes, epoxide hydrolase and glutathione transferases in rat and human hepatic and extrahepatic tissues.

de Waziers I, Cugnenc PH, Yang CS, Leroux JP, Beaune PH.

J Pharmacol Exp Ther. 1990 Apr;253(1):387-94.

PMID:
2329521
50.

Modulation of cytochrome P450 isozymes in human liver, by ethanol and drug intake.

Perrot N, Nalpas B, Yang CS, Beaune PH.

Eur J Clin Invest. 1989 Dec;19(6):549-55.

PMID:
2515975

Supplemental Content

Loading ...
Support Center